Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.60B |
| Revenue (ttm) | 57.53M |
| Net Income (ttm) | -445.81M |
| Shares Out | 115.83M |
| EPS (ttm) | -4.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,236,096 |
| Open | 13.84 |
| Previous Close | 14.28 |
| Day's Range | 13.57 - 14.29 |
| 52-Week Range | 5.90 - 28.25 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 18.34 (+33.09%) |
| Earnings Date | Feb 26, 2026 |
About NTLA
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration a... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $18.34, which is an increase of 33.09% from the latest price.
News
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Pha...
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ: NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2 P...
US FDA lifts clinical hold on Intellia's nerve disease trail
Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its expe...
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. ( NTLA) Q3 2025 Earnings Call November 6, 2025 6:00 PM EST Company Participants Jason Fredette John Leonard - President, CEO & Director Edward Dulac - Executive Vice Presi...
US FDA places clinical hold on Intellia's two gene-editing treatment trials
Intellia Therapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its two late-stage trials testing an experimental gene-editing therapy for a rare disea...
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard...
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient exp...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ratin...
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling B...
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Why big players are pouring millions in THIS biotech stock
Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and whil...
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concer...